[Assessment of tigecycline use economic impact in first-line therapy for complicated intra-abdominal infections in an Intensive Care Unit].
Ancona
F
F
Partner PricewaterhouseCoopers Advisory SpA, Industry Pharma, Milano, Italia. franco.ancona@it.pwc.com
D000005:Abdomen; D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D003362:Cost-Benefit Analysis / Q000191:economics; D006801:Humans; D007362:Intensive Care Units / Q000191:economics*; D007558:Italy; D008911:Minocycline / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline
Valutazione dell'impatto economico dell'impiego della tigeciclina nelle infezioni intra-addominali complicate, nel primo ciclo di cura, in un reparto di anestesia e rianimazione.